Boston Scientific acquired the small cardiac implant more than a decade ago and committed what the reporting described as “hundreds of millions” toward that purchase. The company, according to the STAT News piece republishing Boston Globe reporting by Elizabeth Koh and Liz Kowalczyk, has continued active commercial efforts for the device even after regulatory and clinical headwinds. The article quoted the observation that the company “won’t stop pushing the Watchman.”
The reporting framed Boston Scientific’s commitment as a long-term commercial program rather than a short-term product play. The company took a device that faced early controversy and regulatory scrutiny and maintained investment in its market roll-out. Reporters noted that the device’s pathway from acquisition to widespread use was neither swift nor uncontroversial. The story did not provide detailed breakdowns of sales figures, promotional budgets, or specific marketing tactics; those details were not reported in the source.
The STAT article summarized earlier coverage of a multi-year debate at the FDA before the device ultimately received approval for a restricted group of patients. The story stated that the approval was limited in scope; it did not list the exact indications covered or the labeling language that accompanied the clearance. Reporters described the regulatory dialogue as protracted, highlighting that the agency and the manufacturer engaged in extended discussions before a decision was issued.
Readers should note that the source did not publish the specific docket items, advisory committee transcripts, or internal FDA memoranda that would explain the agency’s reasoning in granular legal or scientific terms. Nor did the piece provide trial-by-trial adjudication of the device’s pivotal evidence. The article relied on the historical record: an extended review process followed by a constrained approval, and reporters attributed that chain of events to the public record and their reporting.
The piece noted that clinicians around the world have implanted the device in large numbers—more than 800,000 devices were reported as implanted globally. That single aggregate figure appeared in the public excerpt without accompanying stratification by country, indication, operator experience, or patient outcomes. The reporting indicated that doctors have questions about the device even as the manufacturer continues active promotion.
The specific questions clinicians raised were not detailed in the published excerpt. The article made clear that physicians remain engaged in debate about the device’s use, but it did not enumerate the clinical concerns, cite formal surveys of practitioners, or specify the clinical scenarios prompting the most discussion. The STAT/Boston Globe reporting did not provide outcome data, comparisons with alternative therapies, or meta-analytic evidence to answer those clinician questions within the excerpt.
The source also did not report particulars about postmarket surveillance programs, adverse-event rates, operator learning curves, or payer coverage policies tied to the implant. Those remain areas where clinicians and health systems will need transparent, published data to reach informed consensus. The STAT piece republished Boston Globe reporting and signaled clinicians’ ongoing uncertainty; it stopped short of furnishing the empirical detail that would resolve those uncertainties.
Limitations reported in the piece
The publicly available STAT excerpt derives from a STAT+ paywalled story that republished Boston Globe reporting by Elizabeth Koh and Liz Kowalczyk. The accessible text provides an overview of corporate commitment, regulatory history, and the aggregate implant count. The source did not report granular clinical trial results, detailed marketing materials, regulatory documentation such as advisory-committee records, or patient-level safety and efficacy metrics. Those items were not present in the published excerpt and therefore cannot be summarized here.
Next questions left open by the reporting
Which specific clinician concerns are most prevalent? The source did not quantify or classify them. What are the long-term outcomes across the global cohort of implanted patients? The article did not provide that data. How have regulatory decisions and labeling evolved in response to postmarket evidence? The piece did not document such changes. For clinicians and policymakers seeking answers, the reporting identifies gaps but does not supply the trial-level or surveillance-level evidence needed to close them.
The article ends on that concrete limitation: clinicians have questions, the company is pressing ahead commercially, and the public excerpt did not include the detailed clinical or regulatory documentation that would allow independent assessment of claims about safety, effectiveness, or appropriate use of the Watchman implant.